The treatment combining platelet-rich plasma and a non-cross-linked hyaluronic acid compound significantly improved hair density and reduced bald areas in women with androgeneticalopecia, and it's safe with only mild side effects.
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
Finasteride and minoxidil are recommended as first-line treatments for hair loss, with dutasteride and oral minoxidil as stronger options if needed. Hair transplants should only be considered after achieving stability with medication, and non-surgical options are suggested if medications are ineffective.
Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgeneticalopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.
Fluridil, a non-steroidal anti-androgen approved for alopecia in parts of Europe, is noted for its low side effects but is not commonly discussed. The user is inquiring if anyone prefers it over other anti-androgens like Spiro or RU58841.
PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgeneticalopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.